24
Jun
2025

Chongqing Peg-Bio Biopharm Co., Ltd.

Exhibitor at CPHI & PMEC China 2025 stand W8B36, Bio Pharma
About Us

Read more Show less
Categories
more categories Show less
  • CN
  • 2023
    On CPHI since
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI & PMEC China 2025
  • 24 Jun 2025 - 26 Jun 2025
  • Shanghai New International Expo Center
  • Visit us at stand W8B36, Bio Pharma

Products Featured at CPHI & PMEC China 2025

  • Semaglutide Intermediate (Recombinant)

    Product Semaglutide Intermediate (Recombinant)

    Semaglutide is a new 2nd Generation GLP-1RA drug developed by Novo Nordisk. In Dec. 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name: Wegovy, 2.4mg/dose) was approved by...

Recently Visited